These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20478852)

  • 1. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics.
    Obach RS; Ryder TF
    Drug Metab Dispos; 2010 Aug; 38(8):1381-91. PubMed ID: 20478852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
    Iga K
    J Pharm Sci; 2015 Oct; 104(10):3565-77. PubMed ID: 26099559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
    Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man.
    Becquemont L; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P; Beaune P
    Pharmacogenetics; 1998 Apr; 8(2):101-8. PubMed ID: 10022747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
    Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
    Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
    Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
    Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol.
    Usmani KA; Hodgson E; Rose RL
    Chem Biol Interact; 2004 Dec; 150(3):221-32. PubMed ID: 15560889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028.
    Kim H; Yoon YJ; Kim H; Kang S; Cheon HG; Yoo SE; Shin JG; Liu KH
    Toxicol Lett; 2006 Oct; 166(2):105-14. PubMed ID: 16857327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
    Desta Z; Soukhova N; Mahal SK; Flockhart DA
    Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.
    Kasahara M; Suzuki H; Komiya I
    Drug Metab Dispos; 2000 Apr; 28(4):409-17. PubMed ID: 10725309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M; Shindo M; Shimada T
    Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
    Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
    Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam.
    Tang J; Amin Usmani K; Hodgson E; Rose RL
    Chem Biol Interact; 2004 Apr; 147(3):319-29. PubMed ID: 15135087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
    Iga K; Kiriyama A
    Biol Pharm Bull; 2017 Dec; 40(12):2024-2037. PubMed ID: 28993551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.
    Fowler S; Guerini E; Qiu N; Cleary Y; Parrott N; Greig G; Mallalieu NL
    J Pharmacol Exp Ther; 2017 Jan; 360(1):164-173. PubMed ID: 27821711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
    Kasserra C; Assaf M; Hoffmann M; Li Y; Liu L; Wang X; Kumar G; Palmisano M
    J Clin Pharmacol; 2015 Feb; 55(2):168-78. PubMed ID: 25159194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.
    Härtter S; Wang X; Weigmann H; Friedberg T; Arand M; Oesch F; Hiemke C
    J Clin Psychopharmacol; 2001 Apr; 21(2):167-74. PubMed ID: 11270913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.